EGFR and central nervous system cancer: On the other hand, according to the 2021 WHO classification of tumors of the central nervous system, DMGs, H3 K27-altered include H3 wild type with enhancer of zeste homolog inhibitory protein (EZHIP) overexpression and epidermal growth factor receptor (EGFR) mutation in addition to H3 K27M mutation (2).